You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Middle aged man with serious facial expression using tablet while sitting in cafeteria.

This is a fictional patient for illustrative purposes

Nucala is an asthma medicine used to treat patients aged 6 years and above with a particular type of asthma called severe eosinophilic asthma. It is used with other medicines in patients whose asthma is severe and not well controlled with previous treatments. Nucala contains the active substance mepolizumab.

Summary of Product Characteristics

For further information on Nucala, please see the Nucala patient information leaflet (PIL). This link will take you to the electronic Medicines Compendium website which is a non-GSK website.

Summary of Product Characteristics and Patient Information Leaflet (UK)

Information for Patients Prescribed Nucala

This page can help you understand more about your condition and your Nucala medication, but if you have any questions or concerns just ask your doctor, pharmacist or nurse.

I am a patient

Nucala is a registered trademark of the GSK group of companies

If you experience any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine